EXINI announces collaboration with Veterans Affairs in United States on the AI Research Program for Medical Image Analysis

The collaborative program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of Veterans with prostate cancer. Read More here

PSMA-AI

PSMA-AI is the first software in development by EXINI tailored to Progenics’ imaging agent pipeline – 1404 and DCFPyL. The imaging agents attach to a protein called Prostate-Specific Membrane Antigen (PSMA) which is overexpressed on the surface of prostate cancer cells. The agents are labelled with a radioactive molecule detectable by nuclear medicine cameras and used in conjunction with co-registered anatomical images to provide anatomical context to the functional images. 

Central to PSMA-AI is the automatic and quantitative computation of assessments used to detect, localize, quantify and stage both localized and advanced prostate cancer lesions. The technology is based on deep learning and convolutional neural networks that determine a detailed anatomical context from the anatomical images. This information is combined with information from the corresponding PSMA-targeted functional image to assess cancer prevalence and growth. The performance of assessments in hybrid images on patients with prostate cancer by human experts has been statistically validated to improve when provided with the additional information retrieved with PSMA-AI.

EXINI Diagnostics AB 

EXINI Diagnostics AB was established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumour burden in patients with metastatic prostate cancer. This platform has been installed at about 1,000 hospitals worldwide. In 2015, EXINI was acquired by Progenics Pharmaceuticals Inc. for developing patient-centric AI technologies for PSMA-targeted theranostic agents.

exini.com